Carmell announced the execution of a definitive agreement to acquire Elevai Skincare, a leader in physician-dispensed exosome skin and haircare products.WHO: A subsidiary of PMGC Holdings, Elevai is developing and commercializing cutting-edge physician-dispensed skin and haircare applications that focus on science-backed applications for the physician-dispensed market, utilizing cutting-edge technologies to redefine skincare and haircare, including its stem cell exosome technology.Carmell Corporation is a bio-aesthetics company focused on skin and hair health. The Carmell Secretome consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from U.S. Food and Drug Administration-approved tissue banks. Over the past seven years, the company has extensively tested the technology underpinning the Carmell Secretome. The company has developed a novel microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the 14 potentially harmful excipients that other companies commonly use to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.WHY: The acquisition of Elevai represents a strategic move with relatively low upfront costs that aims to integrate Elevai Labs' stem cell–derived exosome technology into Carmell's bio-aesthetic platform.IN THEIR OWN WORDS: Mr.